Compare BioNTech SE - ADR (BNTX) vs Funko Inc (FNKO) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
BioNTech SE - ADR vs Funko Inc — how do they compare? BioNTech SE - ADR trades at $93.44 (market cap $23.31B), while Funko Inc trades at $6.01 (market cap $332.33M). The key difference: BioNTech SE - ADR is far larger — about 70.1× Funko Inc's market cap, and Funko Inc is trading nearer its 52-week high, BioNTech SE - ADR nearer its low. Which is the better fit depends on your goals.
| BNTX | FNKO | |
|---|---|---|
Market Cap | $23.31B | $332.33M |
Sector | Health | Consumer Staples |
52-Week High | $119.34 | $6.35 |
52-Week Low | $83.89 | $2.65 |
Enterprise Value | $6.60B | $552.98M |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
BioNTech (BNTX) trades at $93.27, up 0.51% on the day, with a bullish technical signal from moving averages and neutral oscillators. The company reported Q2 2026 revenue of $106 million, missing expectations, and lowered its full-year sales outlook due to weak COVID-19 vaccine demand. Despite negative net income margins and cash outflows, BNTX maintains a strong cash position of $16.78 billion and is advancing its oncology pipeline with 14 pivotal clinical trials.
The outlook is mixed: analyst consensus is strongly bullish with a $121 price target, but declining COVID revenue and ongoing losses pose significant risks. Investment opportunity hinges on successful pipeline development, while near-term headwinds from vaccine demand softness and leadership transition require careful monitoring.
FNKO trades at $5.86, down 5.33% on the day, amid mixed signals. The stock shows a bullish technical trend with strong moving average support, while oscillators are neutral. Fundamentally, revenue declined to $908.21M in 2025 with a net loss of $67.36M, though recent quarters have beaten EPS estimates. The company maintains a low P/S of 0.35 and appointed a new Chief Commercial Officer in August 2026 to drive growth.
Outlook is cautiously optimistic with improving EBITDA guidance and analyst buy ratings, but risks include persistent net losses, high debt levels, and competitive pressures in the collectibles market. The stock's valuation discount offers potential if profitability strengthens.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
About BioNTech SE - ADR
BioNTech is a Germany-based biotechnology company that focuses on developing cancer therapeutics, including individualized immunotherapy, as well as vaccines for infectious diseases, including COVID-19. The company's oncology pipeline contains several classes of drugs, including mRNA-based drugs to encode antigens, neoantigens, cytokines, and antibodies.
Read more on BNTX →About Funko Inc
Funko Inc is a US-based pop culture consumer products company. It creates whimsical, fun, and different products which enable the customer to express their affinity for their favorite through movie, TV show, video game, musician or sports team. The company holds licenses and the rights to create tens of thousands of characters including Game of Thrones, Walking Dead, Disney, Marvel, Harry Potter, Fallout, and others. Its products include Pop, Dorbz, Mystery Vinyl, Plush, Action Figures, and Others. The company sells its products through a diverse network of retail customers across multiple retail channels, including specialty retailers, mass-market retailers, and e-commerce sites.
Read more on FNKO →
